CalciMedica shares slipped by 2.1% on Tuesday, with trading volume falling to 44,801 shares, a 51% decrease from the average session volume of 92,307 shares. This follows a previous session close that was slightly higher. The reduced turnover underscores cooling investor activity as the stock navigates recent clinical progress and market dynamics.

One research firm reiterated a “sell (d-)” rating on CalciMedica earlier this month, while another maintains a “buy” stance. The consensus recommendation stands at “hold,” based on two independent research notes. Analysts project an average price target of 16.00, suggesting limited near-term upside from current levels.

The company reports a debt-to-equity ratio of 1.39 and maintains strong liquidity, with a quick ratio of 4.04 and a current ratio of 4.03. Market capitalization stands at 82.56 million, and the trailing price-to-earnings ratio is negative 3.54, reflecting ongoing investment in research and development. In its latest quarterly release, CalciMedica reported adjusted loss per share of 0.39, beating consensus expectations by 0.02. Sell-side forecasts anticipate an annual loss per share of 2.21, underscoring the firm’s continued focus on advancing its lead candidate through pivotal clinical trials.

Several large investors increased their positions in the third quarter: Stonehage Fleming Financial Services established a new stake valued at 165,000, Meritage Portfolio Management boosted its share count by 33.8% to hold 61,539 shares (valued at 189,000), and Sheets Smith Investment Management added a new position worth 157,000. In the second quarter, Cetera Investment Advisers raised its stake by 33.1% to 36,385 shares (58,000), and Sound View Wealth Advisors Group initiated a position of 32,000. These moves indicate selective accumulation ahead of anticipated clinical milestones.